quant Healthcare Fund

A Sectoral/Thematic Fund scheme from quant Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF966L01CD0).

NAV ₹19.1839 on 16 November 2026.

Expense ratio

Total expense ratio 1.62% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 0.77%, brokerage 0.12%, transaction costs 0.03%, statutory levies including GST 0.70%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year20.1%16.6%-10.3%0.790.87
3 years21.1%17.6%-25.2%0.800.75

Too little NAV history for the 5, 10-year figures.

Category rank: 13th of 13 Direct-Growth funds in Sectoral/Thematic Fund — Pharma, by 3-year Sortino ratio.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 66.4% of the portfolio.

  1. TREPS 02-Nov-2026 DEPO 10 (cash (TREPS)) — 21.10%
  2. Zydus Lifesciences Limited — 10.25%
  3. Divi's Laboratories Limited (derivative) — 9.92%
  4. Aurobindo Pharma Limited — 9.83%
  5. Glenmark Pharmaceuticals Limited (derivative) — 9.38%
  6. GlaxoSmithKline Pharmaceuticals Limited — 8.89%
  7. Strides Pharma Science Limited — 8.79%
  8. Torrent Pharmaceuticals Limited (derivative) — 8.46%
  9. Pfizer Limited — 7.14%
  10. IPCA Laboratories Limited — 5.37%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.